Cardiac Resynchronization Therapy Devices (CRT)

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according to preliminary hot line results presented at the 201...

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.

August 11, 2014 — Medtronic announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-...

The U.S. Food and Drug Administration (FDA) approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization defibrillators (CRT-D), expanding the indication for u...

Medtronic AdaptResponse Global Clinical Trial Cardiac Resynchronization Therapy
Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient...
September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease...
August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva...
Biotronik announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization...
Medtronic Viva Quad XT CRT-D Adaptiv CRT
Medtronic received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad
Medtronic offers an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -...
Biotronik’s Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D...
Biotronik announced the U.S. Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-...

Articles

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease...
May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when...
Medtronic announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac...
ICD, MADIT-CRT trial, long-term followup, ACC.14
Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with...

Video Center

As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
2 weeks 4 days ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
8 weeks 3 days ago
A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost...
10 weeks 5 days ago
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...
Centricity Cardio Enterprise, Cardiac PACS, Cardio PACS, CVIS
This webinar demonstrates the Centricity Cardio Enterprise Solution (CCE), a solution that can help cardiology departments and hospital administrators to...